Coronary heart disease (CHD) is a major cause of mortality in systemic lupus erythematosus (SLE). This ‘accelerated atherosclerosis’ is due to a combination of traditional risk factors such as hypertension and hyperlipidemia, and also disease-related factors such as chronic inflammation. Recent work has provided valuable insights into the relative contribution of various risk factors and also identified novel risk factors. An understanding of risk factors is fundamental to the prevention of CHD in SLE. In this review, we will discuss the role of risk factors for CHD in SLE and offer some strategies for their assessment and management.
NikpourMUrowitzMBGladmanDD. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am2005; 31: 329–354. vii–viii.
2.
NikpourMUrowitzMBGladmanDD. Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep2009; 11: 248–254.
3.
UrowitzMBBookmanAAKoehlerBEGordonDASmytheHAOgryzloMA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med1976; 60: 221–225.
4.
BruceIN. ‘Not only but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford)2005; 44: 1492–1502.
5.
ManziSMeilahnENRairieJE. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol1997; 145: 408–415.
6.
MokCCKwokCLHoLYChanPTYipSF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum2011; 63: 1182–1189.
7.
UrowitzMBGladmanDDTomBDIbanezDFarewellVT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol2008; 35: 2152–2184.
8.
BernatskySBoivinJFJosephL. Mortality in systemic lupus erythematosus. Arthritis Rheum2006; 54: 2550–2557.
9.
ShahMAShahAMKrishnanE. Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. J Rheumatol2009; 36: 570–575.
10.
EsdaileJMAbrahamowiczMGrodzickyT. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum2001; 44: 2331–2337.
PetriMPerez-GutthannSSpenceDHochbergMC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med1992; 93: 513–519.
13.
BruceINUrowitzMBGladmanDDIbanezDSteinerG. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum2003; 48: 3159–3167.
14.
NikpourMGladmanDDIbanezDHarveyPJUrowitzMB. Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: A longitudinal cohort study. Arthritis Research Ther2010; 12: R125–R125.
15.
BruceINUrowitzMBGladmanDDHallettDC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol1999; 26: 2137–2143.
16.
Karp I, Abrahamowicz M, Fortin PR, et al. Longitudinal evolution of risk of coronary heart disease in systemic lupus erythematosus. J Rheumatol 2012; 39: 968–973.
17.
NikpourMUrowitzMBIbanezDHarveyPJGladmanDD. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: A prospective proof-of-concept cohort study. Arthritis Res Ther2011; 13: R156–R156.
18.
NikpourMTolozaSIbanezDGladmanDDUrowitzMB. Defining low-density lipoprotein cholesterol cut-points for coronary artery disease risk stratification in systemic lupus erythematosus. Arthritis Rheum2007; 56: S465–S465.
19.
RahmanPAgueroSGladmanDDHallettDUrowitzMB. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus2000; 9: 672–675.
20.
GustafssonJSimardJFGunnarssonI. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther2012; 14: R46–R46.
21.
CostenbaderKHWrightELiangMHKarlsonEW. Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. Arthritis Rheum2004; 51: 983–988.
22.
NelsonMERejeskiWJBlairSN. Physical activity and public health in older adults: Recommendation from the American College of Sports Medicine and the American Heart Association. Circulation2007; 116: 1094–1105.
23.
AlbertiKGEckelRHGrundySM. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation2009; 120: 1640–1645.
24.
ParkerBBruceIN. The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am2010; 36: 81–97. viii.
25.
LibbyPOkamotoYRochaVZFolcoE. Inflammation in atherosclerosis: Transition from theory to practice. Circulation J2010; 74: 213–220.
26.
IbanezDGladmanDDUrowitzMB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol2005; 32: 824–827.
27.
IbanezDUrowitzMBGladmanDD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol2003; 30: 1977–1982.
28.
KarpIAbrahamowiczMFortinPR. Recent corticosteroid use and recent disease activity: Independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?Arthritis Rheum2008; 59: 169–175.
29.
UrowitzMBIbanezDGladmanDD. Atherosclerotic vascular events in a single large lupus cohort: Prevalence and risk factors. J Rheumatol2007; 34: 70–75.
30.
PearsonTAMensahGAAlexanderRW. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation2003; 107: 499–511.
31.
OckeneISMatthewsCERifaiNRidkerPMReedGStanekE. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem2001; 47: 444–450.
32.
RidkerPMDanielsonEFonsecaFA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359: 2195–2207.
33.
NikpourMGladmanDDIbanezDUrowitzMB. Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. Lupus2009; 18: 966–973.
34.
NikpourMGladmanDDIbnezDHarveyPJUrowitzMB. High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. Arthritis Rheum2012; 64: 3052–3053.
35.
WitztumJL. The oxidation hypothesis of atherosclerosis. Lancet1994; 344: 793–795.
36.
VaaralaO. Antibodies to oxidised LDL. Lupus2000; 9: 202–205.
37.
McMahonMGrossmanJSkaggsB. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum2009; 60: 2428–2437.
38.
McMahonMGrossmanJFitzGeraldJ. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum2006; 54: 2541–2549.
39.
NarshiCBGilesIPRahmanA. The endothelium: An interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?Lupus2011; 20: 5–13.
PetriMLakattaCMagderLGoldmanD. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med1994; 96: 254–259.
42.
TangCGodfreyTNikpourM. Hydroxychloroquine in lupus: Emerging evidence supporting multiple beneficial effects. Intern Med J2012; 42: 968–978.
43.
Ruiz-IrastorzaGRamos-CasalsMBrito-ZeronPKhamashtaMA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis2010; 69: 20–28.
44.
ShinjoSKBonfaEWojdylaD. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis Rheum2010; 62: 855–862.
45.
AsanumaYOeserAShintaniAK. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med2003; 349: 2407–2415.
46.
LimaDSSatoEILimaVCMirandaFJrHattaFH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol2002; 29: 292–297.
47.
ManziSSelzerFSutton-TyrrellK. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum1999; 42: 51–60.
48.
SelzerFSutton-TyrrellKFitzgeraldSTracyRKullerLManziS. Vascular stiffness in women with systemic lupus erythematosus. Hypertension2001; 37: 1075–1082.
49.
NikpourMGladmanDDIbanezDBruceINBurnsRJUrowitzMB. Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. J Rheumatol2009; 36: 288–294.
50.
ElliottJRManziSSattarA. Carotid intima-media thickness and plaque predict future cardiovascular events in women with systemic lupus erythematosus. Arthritis Rheum2008; 58(Suppl S): S413–S413.
51.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation2002; 106: 3143–3421.
52.
GrundySMCleemanJIMerzCN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation2004; 110: 227–239.
53.
PetriMAKianiANPostWChristopher-StineLMagderLS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis2011; 70: 760–765.
54.
VandvikPOLincoffAMGoreJM. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012; 141: e637S–e668S.
55.
CraigSRAminRVRussellDWParadiseNF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med2000; 15: 395–399.
56.
NikpourMUrowitzMBIbanezDGladmanDD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum2009; 61: 1152–1158.
